Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

Phillips, Kristin M.; Pinilla‐Ibarz, Javier; Sotomayor, Eduardo M.; Lee, Morgan; Jim, Heather; Small, Brent J.; Sokol, Lubomir; Lancet, Jeffrey E.; Tinsley, Sara; Sweet, Kendra; Komrokji, Rami S.; Jacobsen, Paul B.

doi:10.1007/s00520-012-1630-5

Cited by 101 publications

(66 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies focused on a real-life setting, however confirming a reduction of perceived QoL during TKI therapy, an association between QoL and treatment satisfaction, and a possible increase of QoL with prolongation of therapy [54][55][56].…”

Section: Second-generation Tkismentioning

confidence: 99%

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

Marchi

Medeot

Fanin

et al. 2016

Expert Review of Hematology

View full text Add to dashboard Cite

Introduction: Patients reported outcome (PRO) are still under-used in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), though data on the correlation between quality of life (QoL) and therapeutic efficacy are increasingly known. Chronic low-grade toxicities can reduce patient's QoL and negatively impact on adherence. Areas covered: This review will focus on the role of QoL questionnaires in patients with CML, receiving imatinib or newer TKIs (dasatinib, nilotinib, bosutinib, ponatinib). Physicians tend to underestimate the impact of TKI-related symptoms, in particular fatigue, that negatively affect QoL and can be a reason of poor adherence to therapy, with detrimental effect on long-term response. Few studies pointed out the role of PRO in CML, and there is paucity of questionnaires specifically designed for CML patients. Expert commentary: We recommend a wider use of PRO to join the pursuit of a rapid and deep responses with an optimization of QoL.ARTICLE HISTORY

show abstract

Section: Second-generation Tkismentioning

confidence: 99%

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

Marchi

Medeot

Fanin

et al. 2016

Expert Review of Hematology

View full text Add to dashboard Cite

show abstract

“…6 Although the majority of patients with CML have good responses to TKI therapy and live for many years, the quality of life is much lower than normal. 7 In addition, over the past decade, some patients still did not respond adequately to imatinib, and ~25% showed primary imatinib resistance. 6 Arsenic, a traditional Chinese medicine, has been widely employed for .2,000 years.…”

mentioning

confidence: 99%

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells

Shi

Liu

et al. 2016

IJN

View full text Add to dashboard Cite

“…Additionally, patient quality of life (QoL) and symptom burden are also important considerations in TKI selection. For instance, compared to controls without CML, CML patients on TKI therapy are more likely to report significantly worse symptoms such as fatigue, depression and nausea, as well as significantly worse symptom burden, role limitations and physical QoL 11,12 . Initiating a therapy that is ineffective may result in resistance or intolerance (i.e., treatment failure) followed by substantial economic consequences, which may increase for patients failing multiple therapy lines.…”

Section: Introductionmentioning

confidence: 99%

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

McGarry

Chen

Divino

et al. 2015

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data. Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ! 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences. Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p ¼ 0.021, Á$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16-2.64), and 73% higher medical costs (95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly. Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure.

show abstract

Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

Abstract: These data suggest the need for interventions to address QOL in CML patients taking TKIs.

Cited by 101 publications

References 20 publications

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

How could patient reported outcomes improve patient management in chronic myeloid leukemia?

Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

Contact Info

Product

Resources

About